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A B S T R A C T
Background
Patients with chronic non-cancer pain who are prescribed and are taking opioids can have a history of long term high dose opioid use
without effective pain relief. In those without good pain relief, reduction of prescribed opioid dose may be the desired and shared goal
of both patient and clinician. Simple unsupervised reduction of opioid use is clinically challenging, and very difficult to achieve and
maintain.
Objectives
To investigate the effectiveness of different methods designed to achieve reduction or cessation of prescribed opioid use for the
management of chronic non-cancer pain.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 8th April
2013, as well as bibliographies.
Selection criteria
Included studies had to be randomised controlled trials comparing opioid users receiving an intervention with a control group receiving
treatment as usual, active control, or placebo. The aim of the study had to include a treatment goal of dose reduction or cessation of
opioid medication.
Data collection and analysis
We sought data relating to prescribed opioid use, adverse events of opioid reduction, pain, and psychological and physical function.
Main results
Two studies provided information on 86 participants. One compared electroacupuncture with sham acupuncture for 20 minutes twice
a week for six weeks; there was no difference between treatments. The other followed 11 weeks of cognitive behavioural therapy with
either therapeutic interactive voice response through a computer for four months or usual treatment; the active group had a significant
reduction in opioid use, while the usual care group had a significant increase.
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Authors’ conclusions
Both included studies were at significant risk of bias because of their small size, together with other important issues, including blinding.
Because of this risk and the paucity of relevant studies, no conclusions can be drawn regarding the effectiveness of interventions for
opioid withdrawal in chronic non-cancer pain.
P L A I N L A N G U A G E S U M M A R Y
Reducing prescribed opioid use in chronic non-cancer pain
About 1 in 5 adults suffer from moderate or severe chronic pain that is not caused by cancer. Some people with this type of pain are
treated with opioids (typically with drugs like morphine, codeine, oxycodone, fentanyl, or buprenorphine, either as tablets or as patches
placed on the skin). It is not unusual for this medication to be ineffective or to stop working over time, and, sometimes, effective
pain relief is not achieved despite doses being increased. Stopping using opioid drugs is not easy, especially when they have been used
for some time, because stopping abruptly can cause unpleasant side effects. This review looked for high quality studies (randomised
controlled trials) of treatments to help people safely stop taking opioids prescribed for their pain. Only two studies were found, and
they investigated only 86 people. No conclusions can be drawn from this small amount of information. Non-randomised studies, not
included in this review, do indicate that in most people intensive rehabilitation packages can bring about major reduction in opioid
use. Reducing prescribed opioid use in chronic non-cancer pain is an important topic in need of more research.
B A C K G R O U N D
Chronic pain of moderate or severe intensity and lasting six
months or longer affects around 20% of adults and imposes signif-
icant reduction in quality of life (Moore 2013). Opioids have long
been used in the treatment of acute and cancer pain, and over the
last two decades there has been amarked increase in their prescrip-
tion for chronic non-cancer pain (CNCP), especially in the US,
Australia, and Europe. Estimates of the numbers of people with
chronic non-cancer pain treated with opioids are not commonly
available, but one estimate for the UK indicates that almost one
million people may use some form of opioid (Gallagher 2009).
Several randomised controlled trials suggested that opioids pro-
vide modest pain relief in the short to medium term (typical trial
duration is 12 weeks; Kalso 2004; Furlan 2006). However, there
is much less evidence that opioids provide long term pain relief
in CNCP (ASIPP 2012; Noble 2010), especially when statistical
imputation methods where withdrawal for any reason is regarded
as treatment failure (and relevant to clinical practice) are used in
favour of carrying the last observed pain readings to the end of the
trial and using that measurement to estimate efficacy despite the
patient not taking the medicine (not, therefore, relevant to clinical
practice) (Moore 2012; Steiner 2011).
Adverse events, principally sedation, impaired cognitive func-
tion, depression, constipation, and bladder dysfunction, are also
common during opioid therapy (Benyamin 2008), with up to
80% of users suffering at least one adverse event (BPS 2010;
Moore 2005). Long-term opioid use can be associated with im-
mune systemdepression, hormonal disturbances, and hyperalgesia
(Benyamin 2008), as well as fractures (Miller 2011), and increased
all-cause mortality in older people compared with other analgesics
(Solomon 2010). Opioid use also carries risks of tolerance, depen-
dence, and abuse.
Practicalities of the real world like prescribing restrictions for non-
opioid analgesics, or guidelines that suggest early use of opioids,
can mean that many patients are prescribed opioid drugs, some-
times inappropriately. The American Society of Interventional
Pain Physicians suggests that the majority of patients who start
chronic opioid treatment continue with the treatment throughout
their life (ASIPP 2012). On occasion, opioid doses are increased
as a result of insufficient analgesia or the development of tolerance
(ie, requiring a higher dose to obtain the same therapeutic benefit).
This can lead to patients being prescribed very high doses of opi-
oids, but still without acceptable pain relief. American opioid sales
quadrupled between 1999 and 2010 (ASIPP 2012). In the US,
increased prescribing is associated with higher rates of overdose
and overdose death (Paulozzi 2011), but with an indication that
60% of CNCP opioid deaths occurred while opioids were used
as directed (ASIPP 2012). The link between opioid prescribing
and opioid-related death is unclear, but rapid increases in opioid
prescribing are being seen in Australia (Leong 2009), and in Eng-
land there was a 101% increase in the number of prescriptions for
2Interventions for the reduction of prescribed opioid use in chronic non-cancer pain (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
strong opioids between 2004 and 2011 (NHS Information Centre
2012).
A number of professional societies worldwide have produced guid-
ance advocating/promoting the judicious and careful use of opi-
oids. The American Academy of Pain Medicine, the American
Pain Society, and the American Society of Addiction Medicine
jointly advise that health care providers should exercise caution
when prescribing opioids, assessing circumstances and suitability
on an individual basis (Chou 2009). Guidance in Washington
State (Washington State Agency Medical Group 2010) has passed
into law (HB2876 2010). Current UK guidance is typical in that
it recognises that prescription opioids can lead to problem use,
and that there is considerable uncertainty in the literature about
any long term benefits of continued use. The British Pain Society
guidance on opioids for persistent pain (BPS 2010) is particularly
cautious. Similar cautions have been raised for prescribers in Aus-
tralia (McDonough 2012).
There is growing concern that the widespread use of opioids has
public health implications (Stannard 2012). The balance between
benefit and risks generated during long term therapy with opioids
suggests that it may be neither clinically effective nor in patients’
best interests to continue opioid prescription without adequate
pain relief. There is, therefore, a potential need to facilitate and
maintain opioid dose reduction. For many patients it is likely
that long-term opioid treatment is continued even when benefit
is not demonstrated, and greater patient benefits may accrue from
opioid withdrawal. Patients who do not benefit from treatment in
terms of pain, or who suffer unacceptable adverse events, should
be helped to cease opioid treatment whilst concurrently addressing
their pain (Ballantyne 2003).
There is a growing recognition that many patients will reach a
state where the reduction of prescribed opioids is the desired and
shared goal of both patient and clinician. This state is sometimes
reached after a history of long term high dose opioid use, making
simple unsupervised cessation clinically challenging, if not impos-
sible. This may occur, at least in part, because of the reluctance of
patient and prescriber to reduce opioid dose for fear of worsening
pain, as well as issues of dependence and subsequent withdrawal
symptoms.
There are many studies of methods of withdrawal from opioids;
most, however, are undertaken in the context of addiction ser-
vices for patients with an opioid abuse problem. Our interest here
was in the planned reduction or total withdrawal of opioids pre-
scribed for pain management. Common opioid reduction tech-
niques in the addiction field are instructive and include opioid
replacement stabilisation and dose tapering and may involve psy-
chological treatments (Amato 2011). Inducing withdrawal under
sedation using opioid antagonists such as naloxone, naltrexone,
or nalmefene is possible (Gowing 2009; Gowing 2010) but is not
recommended owing to unacceptable risks of adverse events. It is
unclear whether similar interventions are effective when adjusted
to CNCP in which treatment aims differ, or if other approaches
are more appropriate.
Description of the condition
Patients
1. with chronic pain of a non-cancer-related origin
2. who are prescribed opioid medication for pain management
3. who have a treatment goal of dose reduction or cessation of
opioid medicine
Description of the intervention
The intervention may be any clinical method that aims to facilitate
opioid withdrawal or dose reduction as a compulsory or optional
aspect of treatment, as either a primary or a secondary outcome.
The intervention could be pharmacological, physiological, psy-
chological, or another, as long its methods are documented clearly
within the study.
How the intervention might work
Different methods will have different mechanisms. In particular,
we expect non-pharmacological treatment aimed at opioid reduc-
tion to operate principally through behaviour change, and phar-
macological methods to operate principally by reducing or man-
aging the adverse events of opioid use or opioid withdrawal.
Why it is important to do this review
Increased prescribing of opioids is a problem because of their po-
tential to cause harm, along with issues of limited relief and toler-
ance. Given the known risks of opioid therapy, it is appropriate to
continue to prescribe opioid medicines only to those patients for
whom the treatment produces acceptable benefits, weighed against
any adverse events. Given evidence in many societies of huge in-
creases in the use of medicinal opioids for CNCP, their limited
effectiveness, and their adverse event profile, we can reasonably
expect a large increase in patients seeking clinical help to reduce
or halt opioid consumption. An evidence summary of the most
effective methods is needed, along with guidance on treatment
development.
O B J E C T I V E S
To investigate the effectiveness of different methods designed to
achieve reduction or cessation of prescribed opioid use for the
management of CNCP.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Included studies had to be randomised control trials (RCTs) com-
paring opioid users receiving an intervention with a control group
receiving treatment as usual, active control, or placebo. The aim
of the study had to include a treatment goal of dose reduction or
cessation of opioid medicine.
Types of participants
Participants were adults (18 years of age or older) using prescrip-
tion opioids for management of chronic non-cancer pain with a
duration of at least three months. Pain conditions could include
but were not limited to: neuropathic pain, myofacial pain, back
pain, fibromyalgia, headache, abdominal, neck or musculoskeletal
pain.
We excluded studies involving only participants with issues of
addiction, abuse, dependence, or non-prescribed opioid use, and
involving participants using opioids for pain relief during palliative
care. This is because the aims of treatment for these populations
differ substantially from those for the population of interest.
Types of interventions
We planned to include in this review a large variety of interven-
tion types. Interventions could be based in pharmacology, physi-
ology, psychology, spirituality, or another approach, provided that
the underpinning methodology was well documented in the study
and was valid. Eligible intervention types could include opioid
antagonist treatment, dose tapering, or opioid replacement with
other pain relieving medication. Interventions could also involve
physical therapy, massage, disability management, complemen-
tary therapies, or psychological approaches such as cognitive be-
havioural therapy, counselling, and coping techniques.
We excluded studies encompassing only interventions specifically
for opioid addiction, medication overuse, dependence, or with-
drawal symptoms.
Types of outcome measures
We extracted relevant outcomes before treatment, immediately
after treatment, and at follow-up, at least three months later but
no longer than a year. If there were two follow-up time points, the
later would be chosen.
Primary outcomes
The primary outcomes of this review are prescribed opioid use in
adults, and the adverse events related to opioid reduction.
Secondary outcomes
Secondary outcomes are symptom reporting of pain, psychological
functioning, and physical functioning.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL), MEDLINE, and EMBASE from inception to
8th April 2013, for RCTs meeting inclusion criteria, with no re-
strictions placed on language. See Appendix 1, Appendix 2, and
Appendix 3 for the MEDLINE (via Ovid), EMBASE (via Ovid),
and CENTRAL search strategies.
Searching other resources
We searched the reference lists of retrieved papers and carried out a
citation search to identify any potentially eligible papers not found
through the electronic search. We also contacted the authors of
studies identified for inclusion to obtain additional data relevant
to this review and not included in the published articles.
Data collection and analysis
Selection of studies
We filtered search results initially by title and abstract, and ob-
tained full copies of potentially eligible studies. Two review au-
thors read the studies to confirm eligibility, with disagreements
discussed and mediated by a third review author if necessary. After
the search was conducted, we limited the selection of studies to
those published from 2000 onwards, to reflect the major growth
in recent years in opioid prescribing for chronic non-cancer pain.
Data extraction and management
Two review authors extracted data using a standard data extraction
form to include details of participants, intervention method and
duration, quantity and type of opioid used, study design, and
treatment outcomes. We discussed any discrepancies with a third
review author.
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Assessment of risk of bias in included studies
We assessed risk of bias in the included studies using the Cochrane
Collaboration Risk of bias tool to assign judgements of high, low,
or unclear risk of bias to sequence generation, allocation conceal-
ment, blinding, incomplete outcome data, selective reporting, and
any other potential sources of bias in the included studies.
Measures of treatment effect
We planned to use risk ratio (RR) to establish statistical difference,
and number needed to treat for an additional beneficial outcome
(NNT) and number needed to treat for an additional harmful
outcome (NNH) as absolute measures of benefit or harm.
We defined a ’responder’ to treatment as a participant who experi-
enced at least a 50% reduction in opioid consumption, or achieved
complete opioid withdrawal or a reduction of their intake to be-
low ’high’ dose, which we identified as 120 mg/day oral morphine
equivalent. Trials have previously shown that dose-related harms
of taking more than 120 mg/day of opioid drugs outweigh the
benefits (Braden 2010; Morasco 2010; Sullivan 2010), and pub-
lished guidelines, including those of the American Pain Society
and theAmericanAcademyof PainMedicine (Chou 2009), andby
the Washington State Agency Medical Group 2010, recommend
a cut-off at 120 mg/day. A responder also had to have, at worst,
no increase in pain as a result of the intervention. Both aspects of
improvement had to be maintained for at least three months post
intervention.
Unit of analysis issues
The unit of analysis was the individual patient.
Dealing with missing data
Weused the intention-to-treat approach to deal withmissing data.
We would include in the analysis all participants who were ran-
domised to treatment, and those for whom follow-up data were
not available were assumed to be non-responders.
Assessment of heterogeneity
It was anticipated that there would be significant clinical hetero-
geneity between studies (participants, conditions, interventions),
so we planned to pool data using a random-effects model.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses to assess the effect of entry dose
on intervention efficacy, and to compare outcomes between pain
conditions or intervention type if sufficient data were available.
Sensitivity analysis
We planned to perform a sensitivity analysis should we suspect
that studies with high risk of bias were significantly skewing results
of a comparison, removing studies from the analysis to assess their
influence.
R E S U L T S
Description of studies
Results of the search
We found 5195 reports in the original search; we identified 4285
reports after duplicates were removed. We identified ten poten-
tially relevant reports from the titles and abstracts, and of these,
three met the inclusion criteria of the review (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Two studies (three reports) were included in the analysis (Zheng
2008; Naylor 2010), with a total of 90 participants randomised
to treatment, and 86 treated. One study (Naylor 2010) reported
additional useful information in an earlier publication (Naylor
2008). Full details can be found in the Characteristics of included
studies table.
In addition to published data, the authors of the two included
studies provided additional data for the outcomes of pain and
psychological functioning (Appendix 4).
Excluded studies
Seven studies were excluded from analysis. Three did not meet
methodological standards (Crisostomo 2008; Krymchantowski
2003; Townsend 2008), while four did not have opioid reduction
as a primary aim (Hale 2007; Potter 2010;Roland 2011;Weinstein
2006). Full details are available in the Characteristics of excluded
studies table.
Risk of bias in included studies
Both of the studies were at significant risk of bias because of their
small size, plus a number of other issues, includingblinding (Figure
2).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
The two included studies used different interventions, and so re-
sults were not pooled.
Primary Outcomes
Opioid use
Zheng 2008 randomised participants to receive either real elec-
troacupuncture (REA; n = 17) or sham electroacupuncture (SEA;
n = 18) for 20 minutes twice a week for six weeks. Opioid con-
sumption varied considerably within each group, and the mean
consumption at baseline differed between groups, being 462 (±
463) mg/week in the REA group and 296 (± 288) mg/week in
the SEA group. Participants in both groups who completed the
six weeks of treatment (REA = 12; SEA = 14) reported a signifi-
cant reduction in opioid consumption between baseline and the
end of treatment at eight weeks, of 64% and 46% in the REA
and SEA groups, respectively. In an intention-to-treat analysis, the
reductions were 39% and 26%. The difference between groups
was not statistically significant. At follow-up at 20 weeks (REA =
9; SEA = 14), opioid consumption had gradually increased in the
REA group and was significantly higher at 20 weeks than at eight
weeks, while in the SEA group there was no significant change.
Naylor 2010 compared therapeutic interactive voice response
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through a computer for four months with usual treatment, fol-
lowing cognitive behavioural therapy for 11 weeks. The experi-
mental group (n = 26, 14 of whom were using opioids at baseline)
reported a significant decrease in opioid use from baseline at both
four- and eight-month follow-ups, with three participants stop-
ping opioid use entirely. The control group (n = 25, 15 of whom
were using opioids at baseline) significantly increased opioid con-
sumption from baseline to the eight-month follow-up, and three
more participants began opioid treatment. At eight-month follow-
up, the difference in mean opioid dose was significant, with the
experimental group using less than the control group.
Adverse events
Zheng 2008 reported a total of 33 adverse events during the treat-
ment period with REA, and 19 with SEA, none of which were
serious. Opioid-based adverse events decreased from baseline to
eight weeks after treatment by 40% in the REA group and 45%
in the SEA group.
Naylor 2010 did not report on adverse events, but contact with




These numbers are from data supplied by the authors (Appendix
4) and differ very slightly from the published data.
Zheng2008 used theVisual Analogue Scale to assess pain intensity.
Average pain at baseline was 4.9/10 in the experimental group
and 5.6/10 in the control group, and post-treatment scores were
4.2 and 5.4, respectively. No differences were detected between
groups. At 20 weeks average pain scores were 3.6 and 4.6.
Naylor 2010 analysed pain using the McGill Pain Questionnaire,
reported in Naylor 2008 (Naylor 2010). The experimental group
reported a decrease in typical pain from baseline to eight months
from 5.7/10 to 3.4/10, and the control group from 6.8 to 5.7.
The difference between groups was statistically significant.
Physical function
Zheng 2008 did not measure physical function.
Naylor 2010 reported physical function using the SF-36 Physi-
cal Function composite scale. The experimental group showed a
small increase (from 31/100 to 40/100) in functioning over eight
months, while the control group did not (29/100 to 31/100). The
difference between groups was statistically significant.
Psychological function
Both studies utilised the Beck Depression Inventory as a measure
of psychological functioning. The data are those provided by the
authors.
Zheng 2008 reported a significant decrease in depression scores
frombaseline to post-treatment at 8 weeks in the REA group, from
18 to 17. Scores in the SEA group also decreased, from 19 to 15.
At final measurement at 20 weeks, the real electro-acupuncture
groupmean score was 14, and the sham electro-acupuncture group
mean score was 15. There was no significant difference between
the groups.
Naylor 2010 reported a decrease in scores of depression across the
study. The experimental group reported a mean of 17 at baseline,
and 8.1 at 8 month follow-up. The maximum score fell from 29
to 22 in the same period. The control group scored an average of
19 at baseline, with a maximum of 51, decreasing to an average of
15, maximum 37, at 8 month follow-up.
D I S C U S S I O N
Summary of main results
There were no adequate data from which to draw any conclusions
from two small studies with different interventions and only 86
treated participants.
Overall completeness and applicability of
evidence
Because of the very small number of included studies, it was de-
cided to additionally investigate methods of prescription opioid
reduction that were not randomised control trials, in case this was
a more commonly used study design. We looked at papers from
the existing search results and additional reference searching. In-
clusion criteria remained the same as in the main search, excepting
the criteria of randomised control design.
In contrast to the randomised evidence, there was a much larger
body of evidence from observational studies. A three-week, out-
patient, intensive, multidisciplinary pain rehabilitation program
conducted at theMayo Clinic Pain Rehabilitation Center demon-
strated large reductions in medication use, particularly in use of
opioids, in a number of publications in recent years. The three-
week programme included stretching, goal setting, stress manage-
ment, physical therapy, pain management, relaxation, and occu-
pational therapy (Mayo 2013).
Typical opioid use in patients at admission was high, often above
40% and as high as 100%, and at discharge and follow-up was
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low, often below 10%. The analyses were retrospective or longi-
tudinal, and not randomised, but represented an interesting body
of additional data.
Results like these were obtained for 159 patients with fibromyalgia
(Hooten 2007), for 383 patients after fusion or non-fusion spinal
surgery, or no surgery (Crisostomo 2008), in a group of 411 pa-
tients with a wide range of age and non-cancer pain conditions
(Darchuk 2010), and for 634 chronic pain patients of different
smoking status (Hooten 2009). In a group of 213 patients all tak-
ing opioids on admission, the rate of opioid use at discharge was
7% and remained low for as long as six months after admission
(Townsend 2008).
Change in medication use, including opioid medication use,
is a common feature of multimodal and multicomponent pro-
grammes of cognitive behavioural therapy for chronic pain. The
evidence for such programmes in improving disability status and
reducing the impact of mental health outcomes is promising
(Williams 2012). At present, however, it is not possible to extract
and describe the components of such programmes for their effec-
tiveness on medication consumption outcomes, although individ-
ual trials report positive effects. A challenge will be to determine
methods of analysis, if possible, of such treatment packages with
multiple components addressing multiple outcomes.
Others have sought evidence from literature reviews to prevent
opioid over-use, and have put forward what is claimed to be an
evidence-based algorithmic approach (Atluri 2012).
Legislation (HB2876 2010) has had a major effect on opioid pre-
scribing in Washington State, where a de-facto limit of 120 mg
oral morphine equivalent a day is suggested, with higher doses
available after consultation with a specialist. An interim assess-
ment showed that about half of physicians followed guidance on
opioid prescribing, and that about 90% of them found it useful
(DLI 2009). A more recent survey has shown large falls in opioid
prescribing (27%), and in the proportion taking more than 120
mg a day oral morphine equivalents (35%), as well as in opioid-
related deaths (50%) (Franklin 2012).
Quality of the evidence
The randomised trial evidence was generally of low quality.
Potential biases in the review process
We were not aware of any biases in the review process, although
there was a potential for bias in searching for studies. While the
intention to reduce opioid use may have been clear, possible in-
terventions may have been disparate.
Agreements and disagreements with other
studies or reviews
We found no other similar reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There were too few data in this review to permit any comments
about implications for practice.
Implications for research
It is clear thatmore research is needed, but there was little guidance
from the randomised studies included in this review to inform
decisions about the design of future randomised trials, or what
interventions they might investigate. Indeed it is a moot point
whether testing individual interventions is appropriate, given that
extant evidence fromnon-randomised studies indicates that amul-
tifaceted multidisciplinary approach may be preferable.
The Mayo Clinic Pain Rehabilitation Center evidence indicated
that a relatively short multifactorial rehabilitation programme
might be a reasonable place to begin research, as that single centre
appeared to obtain consistently good results. It is possible that the
intensity of delivery of the multifactorial programme is as or more
important than the details of specific components. In which case,
the research agenda becomes one of replication in the first instance,
followed by assessment and evaluation. Delivery of an intensive
rehabilitation programme would probably have to be refined for
particular locations and cultures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Naylor 2010
Methods 11weeks plus 120days duration, randomised, standard care, controlled trial. Assessments
at baseline, post intervention, 4 months, and 8 months post intervention
Participants Diagnosis: chronic musculoskeletal pain
55 participants randomised, 51 participants received allocated intervention
Female 44, Male 7
Mean age 46 (SD ± 11.5) years
Interventions Prerandomisation cognitive behavioural therapy (all participants, n = 55)
Therapeutic Interactive Voice Response (n = 26)
Standard care (n = 25)
Outcomes Prescribed medication use: dose and frequency of opioid analgesics, non-steroidal anti-
inflammatory drugs, benzodiazepines, and antidepressants
Pain: Short Form McGIll Pain Questionnaire (MPQ), Pain Symptoms sub scale from
the Treatment Outcomes in Pain Survey (TOPS)
Psychological function: Beck Depression Inventory (BDI), SF-36 Mental Function
Scale, Coping Strategies Questionnaire (CSQ)
Physical function: SF-36 Physical Function Scale, TOPS Total Pain Experience Scale
Notes 4 participants were excluded following randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’randomized using a stratified block design’
Allocation concealment (selection bias) Low risk ’consecutively numbered, sealed envelopes
were prepared for each gender group by the
statistician’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
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Naylor 2010 (Continued)
Selective reporting (reporting bias) Low risk Comprehensive reporting of outcomes
Size High risk 25/26 per group
Zheng 2008
Methods 20 weeks, randomised, single blind, sham controlled trial
Assessments at baseline and at 5th, 8th, 12th, 16th, and 20th weeks
Participants 35 participants with non-malignant pain for longer than 3 months, using opioid medi-
cation
Male 18, Female 17
Mean age 50 years
Interventions Electroacupuncture (n = 17) or sham electroacupuncture (n = 18) for 20 minutes twice
per week for 6 weeks
Outcomes Prescribed opioid use: dosage of opioid-like medications and adverse events (type and
frequency)
Pain: pain intensity visual analogue scale; McGIll Pain Questionnaire (MPQ)
Psychological function: Beck Depression Inventory (BDI)
Physical function: none
SF-36 v2 Health Survey
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’block randomisation code was computer
generated and stored in a password pro-
tected computer’
Allocation concealment (selection bias) Unclear risk ’considerable efforts were made to ensure..
.the successful blinding of participants and
researchers’
Comment: method of concealment not
specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’A researcher, who was blinded to the treat-
ment allocation, phoned each participant
to inform them of the schedule’
Participant blinding success was assessed
using Perception of EA Treatment Ques-
tionnaire, with no significant differences
between groups reported
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Zheng 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition is not described adequately
Selective reporting (reporting bias) High risk Last observation carried forward used for
9/35
Size High risk 17/18 per treatment arm
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Crisostomo 2008 Not randomised
Hale 2007 Primary aim of study was not in line with this review
Krymchantowski 2003 < 10 participants in each arm at post-treatment
Potter 2010 Primary aim of study was not in line with this review
Roland 2011 Primary aim of study was not in line with this review
Townsend 2008 Not randomised
Weinstein 2006 Primary aim of study was not in line with this review
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy (via Ovid)
1. exp Pain, Intractable/ or exp Chronic Pain/
2. Fibromyalgia/
3. exp Headache Disorders/
4. exp Arthritis/
5. (pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*).mp.
6. 1 or 2 or 3 or 4 or 5
7. exp Analgesics, Opioid/
8. (morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine).mp.
9. (opioid* or opiate* or papaver).mp.
10. exp Narcotics/
11. 7 or 8 or 9 or 10
12. exp Rehabilitation/
13. rehabilitation.fs.
14. Opiate Substitution Treatment/
15. exp Narcotic Antagonists/




19. ((cogniti* or behaviour* or behavior* or family or psychosocial*) adj5 (therap* or intervention*)).mp.
20. (counsel* or cope or coping).mp.
21. exp Physical Therapy Modalities/
22. exp Mind-Body Therapies/
23. (physical* adj5 therap*).mp.
24. physiotherap*).mp.
25. (biofeedback* or massage* or acupuncture).mp.
26. pastoral care/ or spirituality/
27. Adaptation, Psychological/
28. (well being or well-being or relax* or accept* or meditat* or spiritual*).mp.
29. (withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*).mp.
30. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. 6 and 11 and 30
32. randomized controlled trial.pt.
33. controlled clinical trial.pt.
34. randomized.ab.
35. placebo.ab.
36. clinical trials as topic.sh.
37. randomly.ab.
38. trial.ti.
39. 32 or 33 or 34 or 35 or 36 or 37 or 38
40. 31 and 39
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41. exp animals/ not humans.sh.
42. 40 not 41
43. (post-operative or postoperative).mp.
44. 42 not 43
45. limit 44 to (“young adult (19 to 24 years)” or “adult (19 to 44 years)” or “young adult and adult (19-24 and 19-44)” or “middle
age (45 to 64 years)” or “middle aged (45 plus years)” or “all aged (65 and over)” or “aged (80 and over)”)
Appendix 2. EMBASE search strategy (via Ovid)
1. exp chronic pain/ or exp intractable pain/
2. exp arthritis/
3. (pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*).ti,ab.
4. 1 or 2 or 3
5. exp narcotic analgesic agent/
6. exp narcotic agent/
7. (morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine).ti,ab.
8. (opioid* or opiate* or papaver).ti,ab.
9. 5 or 6 or 7 or 8
10. exp rehabilitation/
11. rh.fs.
12. opiate substitution treatment/
13. exp narcotic antagonist/
14. (diprenorphine or nalmefene or nalorphine or naloxone or naltrexone or methadone or buprenorphine or clonidine or lofexidine
or guanfacine).ti,ab.
15. exp psychotherapy/
16. ((cogniti* or behaviour* or behavior* or family or psychosocial*) adj3 (therap* or intervention*)).ti,ab.
17. exp physiotherapy/
18. exp alternative medicine/
19. ((physical* adj3 therap*) or physiotherap*).ti,ab.
20. (biofeedback* or massage* or acupuncture*).ti,ab.
21. exp counseling/
22. (counsel* or cope or coping).ti,ab.
23. exp religion/
24. adaptive behavior/
25. (well being or well-being or relax* or accept* or meditat* or spiritual*).ti,ab.
26. (withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*).ti,ab.
27. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. 4 and 9 and 27
29. crossover procedure/
30. double-blind procedure/




35. (crossover* or cross over* or cross-over*).mp.
36. placebo*.mp.
37. (double* adj blind*).mp.




42. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
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43. 28 and 42
Appendix 3. CENTRAL search strategy
1. MeSH descriptor Pain explode all trees
2. (MeSH descriptor Fibromyalgia, this term only)
3. (MeSH descriptor Headache Disorders explode all trees)
4. (MeSH descriptor Arthritis explode all trees)
5. (pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*)
6. (#1 OR #2 OR #3 OR #4 OR #5)
7. (MeSH descriptor Analgesics, Opioid explode all trees)
8. (morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine)
9. (opioid* or opiate* or papaver)
10. (MeSH descriptor Narcotics explode all trees)
11. (#7 OR #8 OR #9 OR #10)
12. (MeSH descriptor Rehabilitation explode all trees)
13. Any MeSH descriptor with qualifier: RH
14. (MeSH descriptor Opiate Substitution Treatment explode all trees)
15. (MeSH descriptor Narcotic Antagonists explode all trees)
16. (diprenophine or nalmefene or nalorphine or naloxone or naltrexone or methadone or buprenorphine or clonidine or lofexidine
or guanfacone)
17. (MeSH descriptor Psychotherapy explode all trees)
18. (psychotherap*)
19. ((cogniti* or behaviour* or behavior* or family or psychosocial*) near/5 (therap* or intervention*))
20. counsel* or cope or coping
21. MeSH descriptor Physical Therapy Modalities explode all trees
22. MeSH descriptor Mind-Body Therapies explode all trees
23. physical* near/5 therap*
24. physiotherap*
25. biofeedback* or massage* or acupuncture*
26. (MeSH descriptor Pastoral Care, this term only)
27. (MeSH descriptor Spirituality, this term only)
28. (MeSH descriptor Adaptation, Psychological, this term only)
29. (well being or well-being or relax* or accept* or meditat* or spiritual*)
30. withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*
31. (12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
OR #27 OR #28 OR #29 OR #30)
32. (#6 AND #11 AND #31), from 2002 to 2012
33. MeSH descriptor Pain, Postoperative explode all trees
34. (#32 AND NOT #33), from 2002 to 2012
Appendix 4. Additional data supplied by authors
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Naylor 2010 Baseline Post intervention 4 months 8 months
McGill Typical Pain
TIVR 5.7 ± 1.9 5.5 ± 1.7 4.1 ± 2.2 3.4 ± 2.4
Control 6.8 ± 1.5 5.6 ± 1.6 5.7 ± 1.4 5.7 ± 1.7
BDI
TIVR 16.7 ± 6.5 10.4 ± 6.4 8.1 ± 5.7 8.1 ± 4.8
Control 18.6 ± 11.2 16.7 ± 11.2 16.3 ± 8.3 14.9 ± 8.7
Zeng 2008 Baseline Treatment Post treatment
Weeks 1, 2 Week 5 Week 8 Week 9 Week 12 Week 16 Week 20
Average pain
REA 4.9 ±1.7 4.1 ±2.3 4.2 ± 2.3 3.9 ±1.9 4.0 ±1.8 3.8 ± 1.7 3.6 ± 1.7
SEA 5.6 ±1.7 5.1 ±1.7 5.4 ± 2.4 5.1 ±2.0 5.3 ±2.2 5.0 ± 2.0 4.6 ± 2.1
BDI total
REA 18.4 ± 7.1 15.7 ± 9.7 17.1 ± 8.3 Not measured 13.8 ± 8.1 14.1 ± 9.3 14.0 ± 7.5
SEA 19.0 ± 8.3 16.3 ± 10.9 15.3 ± 9.6 Not measured 14.5 ± 10.8 15.2 ± 12.0 14.7± 13.2
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol JW/EF/CE
Develop a search strategy JW
Search for studies (usually 2 authors) JW/EF
Obtain copies of studies JW
Select which studies to include (2 + 1 arbiter) JW/AM/SD
Extract data from studies (2 authors) JW/SD
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(Continued)
Enter data into RevMan JW/AM/SD
Carry out the analysis JW/AM/SD/CE
Interpret the analysis JW/AM/SD/CE/CS/RK
Draft the final write-up of the review JW/AM/SD/CE
Update the review CE
Content expert name CE/AM/SD/CR/RK
Author responsible for grammar and language ALL
Methodologist name CE
Statistician name Gavin Stewart
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We contacted the authors of studies identified for inclusion to obtain additional data relevant to this review and not included in the
published articles. The original search for studies was intended to be completed without a time limit, but we limited inclusion to studies
published in 2000 and later to reflect major changes since 2000 in prescribing of opioids to large numbers of people with chronic non-
cancer pain; in this way, we worked to ensure that the review would have contemporary relevance.
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